Treatment of an acquired coagulopathy with recombinant activated factor VII in a damage-control patient.
Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal studies and clinical trials that have been reported.
Holcomb
John B
JB
Department of Trauma and Critical Care, University of Texas Health Science Center, Houston, TX 77030, USA.
Hoots
Keith
K
Moore
Fredrick A
FA
D000293:Adolescent; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology*; D001803:Blood Transfusion / Q000706:statistics & numerical data; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007035:Hypothermia / Q000209:etiology / Q000517:prevention & control; D008297:Male; D009104:Multiple Trauma / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012151:Resuscitation / Q000379:methods
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa